Antibiotic resistance in cutaneous Propionobacterium is a global problem. As a general rule, resistance levels are high to macrolides, trimethoprim/sulfamethoxazole and clindamycin, while tetracyclines and levofloxacin have low resistance potential. Newer preparations like doxycycline MR and doxycycline 20 mg are subantimicrobial and may not lead to resistance. Sampling techniques are crucial to determine resistance. Genomic evaluation using 16S ribosomal RNA gene sequencing can be useful in diagnosing mutations and mapping phylotypes of Propionobacterium acnes. Resistance may lead to slow response and relapses. Apart from benzoyl peroxide, azelaic acid, topical dapsone, oral zinc and retinoids, novel molecules with little resistance potential include octadecenedioic acid, phytosphingosine, lauric acid, retapamulin, resveratrol, T-3912 and NB-003. The use of oral retinoids and non-antibiotics like zinc can prevent resistance and help reduce the dependence on antibiotics.

01 Sep 2011·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

In Vitro Antibacterial Activity of NB-003 against Propionibacterium acnes

Q2 · MEDICINE

Article

Author: Sutcliffe, J. ; Martin, A. ; Baker, J. R. ; Hamouda, T. ; McCarthy, A. ; Ciotti, S. ; Pannu, J. ; Ma, L.

ABSTRACT NB-003 and NB-003 gel formulations are oil-in-water nanoemulsions designed for use in bacterial infections. In vitro susceptibility of Propionibacterium acnes to NB-003 formulations and comparator drugs was evaluated. Both NB-003 formulations were bactericidal against all P. acnes isolates, including those that were erythromycin, clindamycin, and/or tetracycline resistant. In the absence of sebum, the MIC 90 s/minimum bactericidal concentrations (MBC 90 s) for NB-003, NB-003 gel, salicylic acid (SA), and benzoyl peroxide (BPO) were 0.5/2.0, 1.0/2.0, 1,000/2,000, and 50/200 μg/ml, respectively. In the presence of 50% sebum, the MIC 90 s/MBC 90 s of NB003 and BPOs increased to 128/1,024 and 400/1,600 μg/ml, respectively. The MIC 90 s/MBC 90 s of SA were not significantly impacted by the presence of sebum. A reduction in the MBC 90 s for NB-003 and BPO was observed when 2% SA or 0.5% BPO was integrated into the formulation, resulting in MIC 90 s/MBC 90 s of 128/256 μg/ml for NB003 and 214/428 μg/ml for BPO. The addition of EDTA enhanced the in vitro efficacy of 0.5% NB-003 in the presence or absence of 25% sebum. The addition of 5 mM EDTA to each well of the microtiter plate resulted in a >16- and >256-fold decrease in MIC 90 and MBC 90 , yielding a more potent MIC 90 /MBC 90 of ≤1/<1 μg/ml. The kinetics of bactericidal activity of NB-003 against P. acnes were compared to those of a commercially available product of BPO. Electron micrographs of P. acnes treated with NB-003 showed complete disruption of bacteria. Assessment of spontaneous resistance of P. acnes revealed no stably resistant mutant strains.

01 Nov 2010·IDrugs : the investigational drugs journal

Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 2.

Author: Walker, Karen

The 50th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held in Boston, included topics covering new therapeutic developments in the field of infectious disease. This conference report highlights selected presentations on research with novel antimicrobial agents. Investigational drugs discussed include the chitin synthase inhibitor nikkomycin Z (Valley Fever Solutions/University of Arizona), the glycosylphosphatidylinositol biosynthesis inhibitor E-1210 (Eisai), the β-1,3-d-glucan synthesis inhibitor MK-3118 (Merck & Co/SCYNEXIS), the metalloenzyme inhibitors VT-1129 and VT-1161 (both Viamet Pharmaceuticals), and the anti-inflammatory nanoemulsion NB-003 (NanoBio).

News (Medical) associated with NB-003 (NeoLogics Bioscience)

22 May 2024

·www.globenewswire.com

Predicine to Present 9 Liquid Biopsy Studies at ASCO 2024

HAYWARD, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc. A leading precision oncology company, announced today that it will present data from 9 ctDNA studies at ASCO 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and drug resistance mechanism studies. The forthcoming data represents significant potential for the practical application of Predicine’s cutting-edge liquid biopsy technology in personalized cancer care, clinical trials, and Companion Diagnostic (CDx) development. Numerous studies to be unveiled at the conference emphasize the distinct advantages of personalized PredicineBEACON™ and methylation-based PredicineALERT™ MRD underscoring the clinical utility of Predicine’s liquid biopsy portfolio in biomarker discovery, therapy selection, MRD monitoring, and drug resistance mechanism analyses. Predicine Oral Presentation PresenterTitle Product Saturday, June 1 | 1:30 pm – 4:30 pm Jian LiA phase 1 study of the small-molecule PD-L1 inhibitor INCB099280 in select advanced solid tumors: Updated safety, efficacy, and pharmacokinetics (PK) results.PredicineCARE™ Full List of Predicine PresentationsAbstract Poster TitleProductSaturday, June 1 | 9:00 am – 12:00 pm2053352Glioma monitoring via longitudinal intracranial cerebrospinal fluid cell-free DNA.PredicineCARE™PredicineSCORE™ Sunday, June 2 | 9:00 pm – 12:00 pm260887Clinical utility of an ultra-sensitive ctDNA NGS assay for the detection and monitoring in HR-positive, HER2-negative breast cancer.PredicineCARE™ Ultra e16604-Non-invasive detection of urothelial carcinoma through ensembled methylation profiles and fragmentomic patterns in urinary cell-free DNA.PredicineEPIC™ e16602-Real-world study of urine-based NGS liquid biopsy in organ preservation therapy of muscle-invasive bladder cancer (MIBC).PredicineBEACON™PredicineALERT™ e12654-Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy.PredicineBEACON™e13076-Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).PredicineCARE™ Monday, June 3 | 1:30 pm – 4:30 pm8587451High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.PredicineEPIC™4600295Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC).PredicineBEACON™ Visit Predicine Booth #14105 at ASCO 2024! Participate in conversations surrounding these groundbreaking studies and explore collaboration opportunities. Our liquid biopsy solutions are designed to be accessible and affordable for global clinical trials, CDx development, and patient testing across the US, EU, China, and the rest of world. Click here to arrange an in-person meeting with the Predicine team at ASCO booth #14105 or click here to schedule an online meeting. To learn more about Predicine, please see our corporate brochure, product portfolio, and visit our website. About Predicine Predicine is a leading molecular insights company committed to advancing precision medicine in oncology. Predicine has developed a proprietary cell-free DNA and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The Predicine portfolio comprises state-of-the-art blood, urine, and tissue-based Next-Generation Sequencing (NGS) assays designed for harmonized global use in research, clinical development, companion diagnostic (CDx) development, and patient testing. With operational hubs in Silicon Valley, Houston, Chicago, and Shanghai, Predicine collaborates with leading biopharma companies, institutions, and governments in personalized healthcare on a global scale. For more information, please visit us on http://www.predicine.com and follow us on LinkedIn or Twitter (X). Contact Information:Predicine, Inc.media@predicine.com

Phase 1ASCO

100 Deals associated with NB-003 (NeoLogics Bioscience)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Preclinical	CN	Neologics Bioscience Inc.	19 Apr 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

NB-003 (NeoLogics Bioscience)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation